Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review.

ABSTRACT:

Background

Pricing and reimbursement (P&R) systems do not normally use public investments in research and development (R&D) as criteria when negotiating the prices and reimbursement of health technologies.

Objective

The objective was to find mechanisms that consider public investment in R&D when negotiating P&R or obtaining a fair return on this public investment METHODS: We conducted a scoping review. A total of four databases (PubMed, Embase, Scopus and Web of Science) and a grey literature information source (Google Scholar) were searched. Eligible articles were published before 2024 and described how public sector investment in R&D is considered in price negotiations or how the public sector can obtain a return on R&D investment.

Results

The review found 28 papers

SUBMITTER: Garcia-Diaz M 

PROVIDER: S-EPMC12790488 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature